While the EU’s Horizon funding program is more often associated with academic research, a sizeable proportion of its funds are invested in the European biotech industry.

This article investigates some challenges for the industry that it hopes to solve, as a new stage of the H2020 program is close to launch. Emmanuel PETIOT, CEO of DEINOVE, comments on the growing threat posed by increasing numbers of drug-resistant bacteria.